US533A - Truss for hermta - Google Patents

Truss for hermta Download PDF

Info

Publication number
US533A
US533A US533DA US533A US 533 A US533 A US 533A US 533D A US533D A US 533DA US 533 A US533 A US 533A
Authority
US
United States
Prior art keywords
pad
band
post
inch
mortises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Publication date
Application granted granted Critical
Publication of US533A publication Critical patent/US533A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
    • A61F5/01Orthopaedic devices, e.g. splints, casts or braces
    • A61F5/24Trusses
    • A61F5/26Trusses with belt springs

Definitions

  • the hinge and brace self adjusting truss consists of a steel vcurved band A bent and hardened with a spring temper so that the spring will extend to suit the size of the body, and extend a little more than half way around the body of the patient
  • this curved band is square sides and flat and half of an inch wide where the two mortises B C pass through which is about one inch from the end from the mortises to the end it tapers in width and thickness and rises about one quarter of an inch, with the end turned over as at D to admit a link7 E holding its width where the mo-rtises pass through about one inch then tapering down to three eighths of an inch and holding that width to the end, and is about one eighth of an inch thick where the mortises pass through about one inch, then gradually tapering two inches to half an eighth and continues that thickness within one inch from the back end and tapering a little and turned over to admit a link, the oval pad F hereafter described is attached to the spring band by the mortise through the band standing about twenty degrees out from
  • the strap M is attached to a metal link nearest to the oval pad with a steel wire spring N attached to it and strap to the other end to pass through a buckle the other end of the band, the strap is secured to the band by a metal link and the end of the strap a buckle O to take up or let out to suitthe size of the patient.
  • the invention claimed by me, the said JosIAH I-IUNGEREORD, and which I desire to secure by Letters Patent consists in The particular mode described of reversing the pad by means of the oblique mortises, and of constructing the post I-I, the brace I, and their appendages, for connecting" the pad to the spring and adjusting it in its place.

Landscapes

  • Health & Medical Sciences (AREA)
  • Nursing (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Description

UNITED sTATEs PATENT oEEioE.
JOSIAH HUNGERFORD, OF DOVER, NEI/V YORK.
TRUSS FOR HERNIA.
Specication of Letters Patent No. 533i, dated December 26, 1837.
To all whom t may concern Be it known that I, IosIAH IIUNGEREORD, of Dover, in the county of Duchess and State of New York, have invented a new and useful Improvement in Trusses; and I do hereby declare that the following is a full and eXact description; andI to enable others skilled in the art to make and use my invention I will proceed to describe its construction and operation, and have also illustrated it by the accompanying drawings.
The hinge and brace self adjusting truss consists of a steel vcurved band A bent and hardened with a spring temper so that the spring will extend to suit the size of the body, and extend a little more than half way around the body of the patient this curved band is square sides and flat and half of an inch wide where the two mortises B C pass through which is about one inch from the end from the mortises to the end it tapers in width and thickness and rises about one quarter of an inch, with the end turned over as at D to admit a link7 E holding its width where the mo-rtises pass through about one inch then tapering down to three eighths of an inch and holding that width to the end, and is about one eighth of an inch thick where the mortises pass through about one inch, then gradually tapering two inches to half an eighth and continues that thickness within one inch from the back end and tapering a little and turned over to admit a link, the oval pad F hereafter described is attached to the spring band by the mortise through the band standing about twenty degrees out from the center line of the band one on each side of the center so that the pad can be reversed on either side to suit the rupture on the patient leaving the shape between the two mortises like the letter V, the rupture pad is metal and of an oval form on the back and upper focus of which is a post of metal with a hole through near the lower end through which passes a staple which connects the post H with the pad the lower end of the post round in such a manner as to admit the post to incline lengthwise of the pad either way from a perpendicular about five degrees with a rounding on each side of the bottom of the-post fork the band to rest on giving the pad a chance for a rotary motion in the spring band, this post connects the pad to the band by inserting through either oft the mortises inthe band setting the lower end of thepad in an angle to suit the patient, the mortises vbeing longer on the outside so the post can turn either way to adjust the pad so that it shall have an equal and uniform pressure on the rupture on the end of the post thatA projects through the band is a groove with a hole through for a pin to hold the brace I the brace is metal and attached to the pad by a staple J passing through one end of the brace down to the lower focus of the pad leaving the otheil end room to lift up and down, the other end of the brace sits down in the groove of the post the brace having four or five holes in that end so that the pin that passes through the post and through either of the holes to suit the patient and adjust the pad, the back pad K is round and of metal and is attached to the back part of the band by a clasp L so that it can be moved either way to suit the size of the pa-V tient and secured by a metal wedge'` to its proper place. The strap M is attached to a metal link nearest to the oval pad with a steel wire spring N attached to it and strap to the other end to pass through a buckle the other end of the band, the strap is secured to the band by a metal link and the end of the strap a buckle O to take up or let out to suitthe size of the patient. Y
The invention claimed by me, the said JosIAH I-IUNGEREORD, and which I desire to secure by Letters Patent consists in The particular mode described of reversing the pad by means of the oblique mortises, and of constructing the post I-I, the brace I, and their appendages, for connecting" the pad to the spring and adjusting it in its place.
JOSIAH HUNGERFORD.
Witnesses:
JOHN WING, JACOB WING.'
US533D Truss for hermta Expired - Lifetime US533A (en)

Publications (1)

Publication Number Publication Date
US533A true US533A (en) 1837-12-26

Family

ID=2060812

Family Applications (1)

Application Number Title Priority Date Filing Date
US533D Expired - Lifetime US533A (en) Truss for hermta

Country Status (1)

Country Link
US (1) US533A (en)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050177171A1 (en) * 2002-02-13 2005-08-11 Merrick Wetzler Surgical drill guide
WO2010031790A1 (en) 2008-09-17 2010-03-25 Basf Se Devices and method for continuous distillative separation of a mixture containing one or more alkanolamine(s)
WO2013174432A1 (en) 2012-05-24 2013-11-28 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Method for the identification of the origin of a cancer of unknown primary origin by methylation analysis
EP2687202A1 (en) 2009-07-31 2014-01-22 F. Hoffmann-La Roche AG Subcutaneous anti-her2 antibody formulation
WO2018160841A1 (en) 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2020163589A1 (en) 2019-02-08 2020-08-13 Genentech, Inc. Diagnostic and therapeutic methods for cancer
EP3698807A1 (en) 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
WO2020226986A2 (en) 2019-05-03 2020-11-12 Genentech, Inc. Methods of treating cancer with an anti-pd-l1 antibody
WO2021062085A1 (en) 2019-09-27 2021-04-01 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021083949A1 (en) 2019-10-29 2021-05-06 F. Hoffmann-La Roche Ag Bifunctional compounds for the treatment of cancer
WO2021097110A1 (en) 2019-11-13 2021-05-20 Genentech, Inc. Therapeutic compounds and methods of use
WO2021127404A1 (en) 2019-12-20 2021-06-24 Erasca, Inc. Tricyclic pyridones and pyrimidones
EP3862630A1 (en) 2020-02-04 2021-08-11 Dongguan Yih Teh Electric Products Co., Ltd Aroma diffuser and fragrance capsule
WO2021250284A1 (en) 2020-06-12 2021-12-16 Eligo Bioscience Specific decolonization of antibiotic resistant bacteria for prophylactic purposes
WO2021257503A1 (en) 2020-06-16 2021-12-23 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
WO2022020716A1 (en) 2020-07-24 2022-01-27 Genentech, Inc. Heterocyclic inhibitors of tead for treating cancer
WO2022036146A1 (en) 2020-08-12 2022-02-17 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2022076462A1 (en) 2020-10-05 2022-04-14 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022171745A1 (en) 2021-02-12 2022-08-18 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives for the treatment of cancer
EP4067347A1 (en) 2016-05-24 2022-10-05 Genentech, Inc. Heterocyclic inhibitors of cbp/ep300 for the treatment of cancer
WO2022251296A1 (en) 2021-05-25 2022-12-01 Erasca, Inc. Sulfur-containing heteroaromatic tricyclic kras inhibitors
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
EP4119583A1 (en) 2008-01-30 2023-01-18 Genentech, Inc. Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
EP4155415A1 (en) 2016-02-29 2023-03-29 Genentech, Inc. Therapeutic and diagnostic methods for cancer
WO2023097195A1 (en) 2021-11-24 2023-06-01 Genentech, Inc. Therapeutic indazole compounds and methods of use in the treatment of cancer
EP4249917A2 (en) 2018-09-21 2023-09-27 F. Hoffmann-La Roche AG Diagnostic methods for triple-negative breast cancer
WO2023191816A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024015897A1 (en) 2022-07-13 2024-01-18 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024013723A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
WO2024033457A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033389A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
EP4335931A2 (en) 2015-05-29 2024-03-13 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for cancer
WO2024091991A1 (en) 2022-10-25 2024-05-02 Genentech, Inc. Therapeutic and diagnostic methods for multiple myeloma

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050177171A1 (en) * 2002-02-13 2005-08-11 Merrick Wetzler Surgical drill guide
EP3698807A1 (en) 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
EP4119583A1 (en) 2008-01-30 2023-01-18 Genentech, Inc. Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
WO2010031790A1 (en) 2008-09-17 2010-03-25 Basf Se Devices and method for continuous distillative separation of a mixture containing one or more alkanolamine(s)
EP2687202A1 (en) 2009-07-31 2014-01-22 F. Hoffmann-La Roche AG Subcutaneous anti-her2 antibody formulation
EP4339212A2 (en) 2009-07-31 2024-03-20 F. Hoffmann-La Roche AG Subcutaneous anti-her2 antibody formulation
WO2013174432A1 (en) 2012-05-24 2013-11-28 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Method for the identification of the origin of a cancer of unknown primary origin by methylation analysis
EP4335931A2 (en) 2015-05-29 2024-03-13 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for cancer
EP4155415A1 (en) 2016-02-29 2023-03-29 Genentech, Inc. Therapeutic and diagnostic methods for cancer
EP4067347A1 (en) 2016-05-24 2022-10-05 Genentech, Inc. Heterocyclic inhibitors of cbp/ep300 for the treatment of cancer
WO2018160841A1 (en) 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer
EP4249917A2 (en) 2018-09-21 2023-09-27 F. Hoffmann-La Roche AG Diagnostic methods for triple-negative breast cancer
WO2020163589A1 (en) 2019-02-08 2020-08-13 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2020226986A2 (en) 2019-05-03 2020-11-12 Genentech, Inc. Methods of treating cancer with an anti-pd-l1 antibody
WO2021062085A1 (en) 2019-09-27 2021-04-01 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021083949A1 (en) 2019-10-29 2021-05-06 F. Hoffmann-La Roche Ag Bifunctional compounds for the treatment of cancer
WO2021097110A1 (en) 2019-11-13 2021-05-20 Genentech, Inc. Therapeutic compounds and methods of use
WO2021127404A1 (en) 2019-12-20 2021-06-24 Erasca, Inc. Tricyclic pyridones and pyrimidones
EP3862630A1 (en) 2020-02-04 2021-08-11 Dongguan Yih Teh Electric Products Co., Ltd Aroma diffuser and fragrance capsule
WO2021250284A1 (en) 2020-06-12 2021-12-16 Eligo Bioscience Specific decolonization of antibiotic resistant bacteria for prophylactic purposes
WO2021257503A1 (en) 2020-06-16 2021-12-23 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
WO2022020716A1 (en) 2020-07-24 2022-01-27 Genentech, Inc. Heterocyclic inhibitors of tead for treating cancer
WO2022036146A1 (en) 2020-08-12 2022-02-17 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2022076462A1 (en) 2020-10-05 2022-04-14 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022171745A1 (en) 2021-02-12 2022-08-18 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives for the treatment of cancer
WO2022251296A1 (en) 2021-05-25 2022-12-01 Erasca, Inc. Sulfur-containing heteroaromatic tricyclic kras inhibitors
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
WO2023097195A1 (en) 2021-11-24 2023-06-01 Genentech, Inc. Therapeutic indazole compounds and methods of use in the treatment of cancer
WO2023191816A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024015897A1 (en) 2022-07-13 2024-01-18 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024013723A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
WO2024033457A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033389A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024091991A1 (en) 2022-10-25 2024-05-02 Genentech, Inc. Therapeutic and diagnostic methods for multiple myeloma

Similar Documents

Publication Publication Date Title
US533A (en) Truss for hermta
US872A (en) Hand-bellows
US41548A (en) Improvement in machines for treating curved spines
US2829A (en) Tettss
US181699A (en) Improvement in wrenches
USD3913S (en) Design for burial caskets
US3571A (en) Epenetus a
US390951A (en) Hitching-post
US53017A (en) Improvement in buckles
US3814A (en) Improvement in grain-cradles
US119233A (en) Improvement in trusses
US200612A (en) Improvement in buck-saw frames
US52745A (en) Andeew eakkin
USRE4697E (en) Improvement in trusses
US79991A (en) Improved teuss-pad
US70683A (en) Charles a
US292547A (en) James dockstadeb
US177340A (en) Improvement in fence-posts
US113623A (en) Improvement in shawl-straps
US146332A (en) Improvement in bridge-trusses
US1226A (en) Tbttss fob the cube of hernia
US3812A (en) Truss
US65520A (en) Geoege e
US1165A (en) Stibrup fob saddles
US55724A (en) Improvement in trusses